Icosavax is a biopharmaceutical company utilizing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Co.'s pipeline includes vaccine candidates targeting some viral causes of pneumonia. Co.'s primary vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus, and IVX-241, a vaccine candidate designed to target human metapneumovirus. Co. is developing additional vaccine candidates to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults. The ICVX YTD return is shown above.
The YTD Return on the ICVX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ICVX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ICVX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|